The Second Circuit Court of Appeals recently ruled that UMB Bank, N.A. can proceed with its lawsuit against Bristol-Myers Squibb Company regarding a trust agreement. This decision, made on August 13, 2026, is significant because it clarifies the standing of trustees in legal disputes involving trust agreements, particularly when the appointment of the trustee is challenged. The case affects UMB Bank, Bristol-Myers, and the holders of contingent value rights (CVRs) associated with a corporate acquisition.
The case originated from a dispute over a Contingent Value Rights Agreement (CVR Agreement) that Bristol-Myers entered into during its acquisition of Celgene, a pharmaceutical company, in 2019. Under this agreement, Bristol-Myers was obligated to make certain payments to CVR holders based on the achievement of specific FDA approvals. UMB Bank was appointed as the trustee of this agreement and later sued Bristol-Myers for allegedly failing to meet its obligations.
Initially, the U.S. District Court for the Southern District of New York dismissed UMB's claims, stating that UMB lacked standing to sue due to alleged defects in its appointment as trustee. Bristol-Myers argued that UMB was not properly appointed according to the terms of the CVR Agreement, which required the majority of registered holders to approve any substitution of the trustee. UMB appealed this decision, leading to the recent ruling from the Second Circuit.
The court found that the district court erred in concluding that UMB lacked standing. It stated, "the injuries to the beneficial owners of securities whose interests the trust was formed to protect constituted cognizable and redressable injuries to the trust." The judges emphasized that any defects in UMB's appointment as trustee related to its capacity to sue, not its standing under Article III of the Constitution.
The ruling clarified that UMB's claims were brought solely in its capacity as trustee and that the beneficial owners of the CVRs had suffered injuries that warranted legal action. The court also noted that even if UMB's initial appointment did not fully comply with the CVR Agreement, the actions of Bristol-Myers and the original trustee indicated acceptance of UMB's role. The judges concluded, "whether characterized as a waiver or ratification, on this record Equiniti’s and Bristol-Myers’ conduct precludes Bristol-Myers’ challenge to UMB’s capacity to act on behalf of the trust."
This ruling has important implications for future cases involving trustees and their authority to sue on behalf of trusts. It reinforces the notion that the standing of a trustee is separate from the procedural aspects of their appointment. This distinction allows trustees to pursue legal remedies for the benefit of trust beneficiaries, even when there are disputes about their appointment.
Moving forward, this decision may impact how trusts are managed and how disputes are resolved in similar contexts. It sets a precedent that could influence other cases involving trustee appointments and the rights of beneficiaries. The ruling underscores the importance of protecting the interests of trust beneficiaries and ensuring that they have avenues for legal recourse when their rights are at stake.
As for what’s next, the case has been sent back to the district court for further proceedings. UMB Bank will now have the opportunity to pursue its claims against Bristol-Myers Squibb. There is no indication that this ruling will be appealed, but it remains to be seen how the district court will handle the case moving forward.